Keros Therapeutics Newsroom

Keros Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesDec 23 20:51

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43

Futu NewsDec 23 20:33

Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating

MT NewswiresDec 23 19:53

Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential

TipRanksDec 23 19:46

Keros Therapeutics Analyst Ratings

BenzingaDec 17 00:21

Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63

Futu NewsDec 16 21:31

Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63

BenzingaDec 16 21:03

Analysts' Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)

TipRanksDec 16 20:56

Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40

Futu NewsDec 16 20:31

Keros Therapeutics Cut to Neutral From Buy by Guggenheim

Dow JonesDec 16 18:28

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)

TipRanksDec 16 13:53

Guggenheim Downgrades Keros Therapeutics(KROS.US) to Hold Rating

Futu NewsDec 16 08:31

Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow JonesDec 14 03:56

Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23

Futu NewsDec 13 23:32

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating

Futu NewsDec 13 21:32

Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44

Futu NewsDec 13 21:31

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84

Futu NewsDec 13 21:00

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Lowers Price Target to $47

BenzingaDec 13 19:36

Keros Therapeutics Cut to Market Perform From Outperform by William Blair

Dow JonesDec 13 03:22

Keros Therapeutics Analyst Ratings

BenzingaDec 13 01:50